Tripep discontinues HIV drug

Tripep (SSE:TPEP) said its Phase II study of GPG tripeptide lysine proline glycine for HIV has not shown significant benefit, and the company discontinued development of the compound. CEO Hans Moeller told BioCentury that an HIV-inhibiting effect of GPG was achieved in 3 out of 27 patients in the trial. He noted that the effect was observed in 5 of 15 treatment-naive HIV patients in a previous Phase II trial. ...